10:55 AM EDT, 03/31/2025 (MT Newswires) -- Avidity Biosciences ( RNA ) said Monday it completed enrollment in the biomarker group in a phase 1/2 trial of delpacibart braxlosiran, or del-brax, in people with facioscapulohumeral muscular dystrophy, a genetic muscle disorder.

The company said 51 participants were enrolled in the biomarker group.

The del-brax biomarker group was designed for a potential accelerated approval in the US, Avidity said, adding it plans to release a regulatory update in Q2.

The company's shares were down 6% in recent trading.

Price: 29.69, Change: -1.91, Percent Change: -6.04